| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Levetiracetam | Epilepsy | Oral solution | 100 mg/ml |
| Levodopa/benserazide | Parkinson | Tablets | 50 mg + 12.5mg 100 mg + 25 mg 200 mg + 50 mg |
| Levomepromazine | Psychosis | Oral solution | 40 mg/ml |
| Levomepromazine | Psychosis | Solution for injection | 25 mg/ml |
| Levomethadone ** | Opioids substitution | Oral solution | 5mg/ ml (bottle 500ml and 1000ml) |
| Levomethadone ** | Severe pain | Oral drops, solution | 5mg/ ml (bottle 20ml) |
| Melperone | Psychomotor agitation and sleep | Film-coated tablets | 10 mg, 25 mg, 50mg and 100 mg |
| Melperone Forte | Psychomotor agitation and sleep | Oral solution | 25mg/ 5 ml |
| Memantine hydrochloride | Alzheimer's disease | Film-coated tablets | 5, 10, 15 and 20 mg |
| Memantine hydrochloride | Alzheimer's disease | Oral solution | 10 mg/ml |
| Methocarbamol | Muscle spasms, pain | Film-coated tablets | 750 mg |
| Methocarbamol | Muscle spasms, pain | Film-coated tablets | 500, 1000 and 1500 mg |
| Midazolam | Epilepsy | Oral solution | 2,5 mg/ 0,5 ml 5 mg/ 1 ml 7,5 mg/ 1,5 ml 10 mg/ 2 ml |
| Olanzapine | Psychosis, schizophrenia | Film-coated tablets | 2.5, 5, 7.5, 10, 15 and 20 mg |
| Olanzapine | Psychosis, schizophrenia | Orodispersable tablets | 5, 10, 15 and 20 mg |
| Opipramol | Depression / Anxiety | Film-coated tablets | 50, 100 and 150 mg |
| Pipamperone | Sleep disorders and psychomotor | Tablets | 40 and 120 mg |
| Pipamperone | Sleep disorders and psychomotor | Oral solution | 20mg/ 5 ml |
| Piracetam | Alzheimer | Film-coated tablets | 800 & 1200 mg |
| Piracetam | Alzheimer | Oral solution | 333 mg/ml |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.